18F-fluorodeoxyglucose position emission tomography (FDG-PET) for monitoring disease activity and treatment response in idiopathic retroperitoneal fibrosis

European Journal of Internal Medicine

Volumn 21, Issue 3, 2010, Pages 216-221

  Jansen, I ^a   Hendriksz, T R ^a   Han, S H ^a   Huiskes, A W L C ^a   van Bommel, E F H ^a  

^a ALBERT SCHWEITZER HOSPITAL   (Netherlands)

Author keywords

Disease activity; FDG PET; Retroperitoneal fibrosis; Tamoxifen; Treatment response

Indexed keywords

C REACTIVE PROTEIN; FLUORODEOXYGLUCOSE F 18; TAMOXIFEN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG MONITORING; FEMALE; HUMAN; IDIOPATHIC DISEASE; IMAGE ANALYSIS; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REMISSION; RETROPERITONEAL FIBROSIS; TREATMENT RESPONSE;

ACUTE-PHASE PROTEINS; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE PROGRESSION; DRUG MONITORING; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECURRENCE; REGRESSION ANALYSIS; RETROPERITONEAL FIBROSIS; TAMOXIFEN; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77952290397     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2010.02.008     Document Type: Article

References (33)

1. Van Bommel E.F.H. Retroperitoneal fibrosis. Neth J Med 60 (2002) 231-242
2. Vaglio A., Salvarani C., and Buzio C. Retroperitoneal fibrosis. Lancet 367 (2006) 241-251
3. Van Bommel E.F.H., Jansen I., Hendriksz T.R., and Aarnoudse A.L.H.J. Idiopathic retroperitoneal fibrosis: prospective evaluation of incidence and clinicoradiological presentation. Medicine 88 (2009) 193-201
4. Van Bommel E.F.H., Siemes C., Hak L.E., van der Veer S.J., and Hendriksz T.R. Long-term renal and patient outcome in idiopathic retroperitoneal fibrosis treated with prednisone. Am J Kidney Dis 49 (2007) 615-625
5. Vos F.J., Bleeker-Rovers C.P., Corstens F.H., Kullberg B.J., and Oyen W.J. FDG-PET for imaging of non-osseous infection and inflammation. J Nucl Med Mol Im 50 (2006) 121-130
6. Blockmans D., Knockaert D., Maes A., De Caestecker J., Stroobants S., Bobbaers H., et al. Clinical value of [18] fluoro-deoxyglucose positron emission tomography for patients with fever of unknown origin. Clin Infect Dis 32 (2001) 191-196
7. Scheel A.K., Meller J., Vosshenrich K., Kohlhoff E., Siefker U., Muller G.A., et al. Diagnosis and follow-up of aortitis in the elderly. Ann Rheum Dis 63 (2004) 1507-1510
8. Kubota K., Yamada K., Yoshioka S., Yamada S., Ito M., and Ido T. Differential diagnosis of idiopathic fibrosis from malignant lymphadenopathy with PET and F-18 fluorodeoxyglucose. Clin Nucl Med 17 (1992) 361-363
9. Salvarani C., Pipitone N., Versari A., Vaglio A., Serafini D., Bajocchi G., et al. Positron emission tomography (PET): evaluation of chronic periaortitis. Arthritis Rheum 53 (2005) 29-303
10. Wewers M.E., and Lowe N.K. A critical review of visual analogue scales in the measurement of clinical phenomena. Res Nurs Health 13 (1990) 27-36
11. Magrey M.N., Husni M.E., Kushner I., and Calabrese L.H. Do acute-phase reactants predict response to glucocorticoid therapy in retroperitoneal fibrosis. Arthritis Rheum 61 (2009) 674-679
12. Vaglio A., Versari A., Fraternali A., Ferrozzi F., Salvarani C., and Buzio C. 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and follow-up of idiopathic retroperitoneal fibrosis. Arthritis Rheum 53 (15 2005) 122-125
13. Cheung W.S., Meller J., Vosshennrich R., Middel P., and Becker W. Ormond's disease: appearance in [F-18]FDG PET imaging. Nucl Med 41 (2002) N44-N47
14. Drieskens O., Blockmans D., Van den Bruel A., and Mortelmans L. Riedel's thyroiditis and retroperitoneal fibrosis in multifocal fibrosclerosis: positron emission tomographic findings. Clin Nucl Med 27 (2002) 413-415
15. Chander S., Ergun E.L., Chugani H.T., Juhasz C., Shields A.F., and Weaver D.W. High 2-deoxy-2-[18F]fluoro-D-glucose accumulation in a case of retroperitoneal fibrosis following resection of carcinoid tumor. Mol Imaging Biol 4 (2002) 363-368
16. Brodmann M., Lipp R.W., Aigner R., and Pilger E. Positron emission tomography reveals extended thoracic and abdominal peri-aortitis. Vasc Med 8 (2003) 127-128
17. Tanabe T., Tsushima K., Yasuo M., Urushihata K., Hanaoka M., Koizumi T., et al. IgG-associated multifocal systemic fibrosis complicating sclerosing sialadenitis, hypophysitis, and retroperitoneal fibrosis, but lacking pancreatic involvement. Int Med 45 (2006) 1243-1247
18. Takahashi M., Momose T., Kameyama M., and Ohtomo K. Abnormal accumulation of [18] fluorodeoxyglucose in the aortic wall related to inflammatory changes: three case reports. Ann Nucl Med 20 (2006) 361-364
19. Sakamoto A., Okamoto K., Ishizaka N., Tejima K., Hirata Y., and Nagai R. 18F-fluorodeoxyglucose positron emission tomography in a case of retroperitoneal fibrosis. Int Heart J 47 (2006) 645-650
20. Agrawal A., Nair N., and Baghel N. 18F-FDG PET in Ormond disease in a patient with renal cell carcinoma. Clin Nucl Med 32 (2007) 320-322
21. Nakajo M., Jinnouchi S., Noguchi M., Uozumi K., Tanabe H., Tateno R., et al. FDG PET and PET/CT monitoring of autoimmune pancreatitis associated with extrapancreatic autoimmune disease. Clin Nucl Med 32 (2007) 282-285
22. Young A.S., Binkovitz L.A., Adler B.H., Nicol K.K., and Rennebohm R.M. Pulmonary hyalinizing granuloma and retroperitoneal fibrosis in an adolescent. Pediatr Radiol 37 (2007) 91-95
23. Young P.M., Peterson J.J., and Calamia K.T. Hypermetabolic activity in patients with active retroperitoneal fibrosis on F-18 FDG PET: report of three cases. Ann Nucl Med 22 (2008) 87-92
24. Nakajo M., Jinnouchi S., Tanabe H., Tateno R., and Nakajo M. 18F-fluorodeoxyglucose positron emission tomography features of idiopathic retroperitoneal fibrosis. J Comput Assist Tomogr 31 (2007) 539-543
25. Vaglio A., Greco P., Versari A., Filice A., Cobelli R., Manenti L., et al. Post-treatment residual tissue in idiopathic retroperitoneal fibrosis: active residual disease or silent "scar"? A study using 18F-fluorodeoxyglucose positron emission tomography. Clin Exp Rheumatol 23 (2005) 231-234
26. Van Bommel E.F.H., Hendriksz T.R., Huiskes A.W.L.C., and Zeegers A.G. Brief communication: tamoxifen therapy for idiopathic retroperitoneal fibrosis. Ann Intern Med 144 (2006) 101-106
27. Versari A., Palmisano A., Fraternali, Cobelli R., Salvarani C., Buzio C., et al. FDG-PET in idiopathic retroperitoneal fibrosis. J Nucl Med 48 Suppl.2 (2007) 288P (Abstract)
28. Tatsumi M., Cohade C., Nakamoto Y., and Wahl R.L. Fluorodeoxyglucose uptake in the aortic wall at PET/CT: possible finding for active atherosclerosis. Radiology 229 (2003) 831-837
29. Fukuchi K., Ishida Y., Higashi M., Tsunekawa T., Ogino H., Minatoya K., et al. Detection of aortic graft infection by fluorodeoxyglucose positron emission tomography: comparison with computed tomographic findings. J Vasc Surg 42 (2005) 919-925
30. Van Bommel E.F., Siemes C., van der Veer S.J., Han S.H., Huiskes A.W., and Hendriksz T.R. Clinical value of gallium-67 SPECT scintigraphy in the diagnostic and therapeutic evaluation of retroperitoneal fibrosis. J Intern Med 262 (2007) 224-234
31. Metser U., and Even-Sapir E. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT. Semin Nucl Med 37 (2007) 206-222
32. Wahl R.L., Jacene H., Kasamon Y., and Lodge M.A. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50 (2009) S122-S150
33. Boellaard R., Oyen W.J., Hoekstra C.J., Hoekstra O.S., Visser E.P., Willemsen A.T., et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging 35 (2008) 2320-2333